Arena Pharmaceuticals (NASDAQ: ARNA) issued its quarterly earnings data on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.07. The company had revenue of $1.94 million for the quarter, compared to the consensus estimate of $21.94 million.
Several analysts have also recently commented on the stock. Analysts at Leerink Swann initiated coverage on shares of Arena Pharmaceuticals in a research note to investors on Wednesday, February 6th. They set an “outperform” rating and a $12.00 price target on the stock. They noted that the move was a valuation call. On a related note, analysts at TheStreet reiterated a “sell” rating on shares of Arena Pharmaceuticals in a research note to investors on Monday, January 28th. Finally, analysts at TheStreet reiterated a “sell” rating on shares of Arena Pharmaceuticals in a research note to investors on Thursday, December 27th.
Three equities research analysts have rated the stock with a buy rating, five have assigned a hold rating, and one has given a sell rating to the company. The company presently has a consensus rating of “hold” and a consensus price target of $9.60.
Shares of Arena Pharmaceuticals (ARNA) opened at 8.34 on Monday. Arena Pharmaceuticals (ARNA) has a 52 week low of $1.70 and a 52 week high of $13.50. The stock’s 50-day moving average is currently $8.76. The company’s market cap is $1.812 billion.
Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.